zanubrutinib plus rituximab in first-line mcl therapy
Published 4 years ago • 140 plays • Length 1:42Download video MP4
Download video MP3
Similar videos
-
1:50
acalabrutinib and rituximab as first-line therapy for older patients with mcl
-
0:26
acalabrutinib plus venetoclax and rituximab in the treatment of mcl
-
2:04
updated long-term follow-up of sequoia: zanubrutinib vs bendamustine-rituximab in untreated cll/sll
-
1:44
triangle: ibrutinib with soc or as a substitute to autologous transplantation in first-line mcl
-
1:05
final analysis of the alpine trial: zanubrutinib vs ibrutinib in r/r cll
-
3:53
treatment approaches for older patients with mcl
-
1:19
zanubrutinib monotherapy in r/r indolent nhl
-
0:55
zanubrutinib in mantle cell lymphoma: updated safety and efficacy data
-
6:45
zanubrutinib demonstrates superior pfs compared with ibrutinib for treatment of r/r cll and sll
-
2:31
the value of btk inhibitors in cll & the future of acalabrutinib in this disease
-
5:41
primary results from the phase iii shine study: ibrutinib br for older patients with mcl
-
1:48
zanubrutinib plus obinutuzumab: cll, sll & fl
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl
-
2:08
cll-rt1 trial: primary endpoint analysis of tislelizumab plus zanubrutinib in patients with rt
-
1:30
bendamustine-rituximab vs ibrutinib as frontline therapy in waldenström's macroglobulinemia
-
1:44
the efficacy of zanubrutinib versus ibrutinib in patients with wm harboring various mutations
-
4:29
first-line ibrutinib vs chemoimmunotherapy in cll: a real-world data analysis
-
1:17
an ongoing phase i/ii study of sonrotoclax zanubrutinib in patients with treatment-naive cll/sll
-
2:18
zanubrutinib for r/r primary cns lymphoma: the initial results of the prizm platform study
-
2:57
selecting between ibrutinib, acalabrutinib and zanubrutinib in the frontline setting in cll
-
1:20
health-related quality of life with zanubrutinib versus ibrutinib for patients with r/r cll
-
2:04
phase i/ii study of a novel bet inhibitor, bms-986158, alone & with ruxolitinib or fedratinib in mf